Philip T - Search Results

1

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T. Blay JY, et al. Among authors: philip t. Cancer Res. 1990 Apr 15;50(8):2371-4. Cancer Res. 1990. PMID: 2317822

2

High-dose chemotherapy in non-Hodgkin's lymphoma.

Blay JY, Philip TO. Blay JY, et al. Among authors: philip to. Cancer Treat Res. 1996;85:87-103. doi: 10.1007/978-1-4615-4129-5_7. Cancer Treat Res. 1996. PMID: 9043777 Review. No abstract available.

3

Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

Philip T, Mercatello A, Negrier S, Philip I, Rebattu P, Kaemmerlin P, Gaspard M, Tognier E, Combaret V, Bijmann JT, et al. Philip T, et al. Among authors: philip i. Cancer Treat Rev. 1989 Jun;16 Suppl A:91-104. doi: 10.1016/0305-7372(89)90028-5. Cancer Treat Rev. 1989. PMID: 2788510

4

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

Philip T, Negrier S, Lasset C, Coronel B, Bret M, Blay JY, Merrouche Y, Carrie C, Kaemmerlen P, Chauvin F, et al. Philip T, et al. Br J Cancer. 1993 Nov;68(5):1036-42. doi: 10.1038/bjc.1993.476. Br J Cancer. 1993. PMID: 8217594 Free PMC article.

5

[Has interleukin 2 modified the outcome of metastatic kidney cancer?].

Négrier S, Philip T. Négrier S, et al. Among authors: philip t. Ann Urol (Paris). 1993;27(2):87-9. Ann Urol (Paris). 1993. PMID: 8503657 French.

6

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC. Bain C, et al. Among authors: philip t. Br J Cancer. 1997;75(2):283-6. doi: 10.1038/bjc.1997.46. Br J Cancer. 1997. PMID: 9010039 Free PMC article.

7

Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.

Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M. Blay JY, et al. Among authors: philip t. Int J Cancer. 1997 Jul 29;72(3):424-30. doi: 10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r. Int J Cancer. 1997. PMID: 9247285 Clinical Trial.

8

Tumor necrosis factor as an autocrine growth factor for neuroblastoma.

Goillot E, Combaret V, Ladenstein R, Baubet D, Blay JY, Philip T, Favrot MC. Goillot E, et al. Among authors: philip t. Cancer Res. 1992 Jun 1;52(11):3194-200. Cancer Res. 1992. PMID: 1317260

9

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

Blay JY, Négrier S, Combaret V, Merrouche Y, Mercatello A, Moskovtchenko JF, Philip T, Favrot M. Blay JY, et al. Among authors: philip t. Bull Cancer. 1992;79(1):55-65. Bull Cancer. 1992. PMID: 1520953 French.

10

[Treatment of renal cancer in adults with interleukin 2].

Negrier S, Mercatello A, Philip T. Negrier S, et al. Among authors: philip t. Rev Prat. 1992 May 15;42(10):1241-5. Rev Prat. 1992. PMID: 1609217 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

466 results

Search Page

Filters